Spatial and molecular profiling of the mononuclear phagocyte network in classic Hodgkin lymphoma.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
11 05 2023
Historique:
accepted: 02 01 2023
received: 04 03 2022
medline: 15 5 2023
pubmed: 10 2 2023
entrez: 9 2 2023
Statut: ppublish

Résumé

Classic Hodgkin lymphoma (cHL) has a rich immune infiltrate, which is an intrinsic component of the neoplastic process. Malignant Hodgkin Reed-Sternberg cells (HRSCs) create an immunosuppressive microenvironment by the expression of regulatory molecules, preventing T-cell activation. It has also been demonstrated that mononuclear phagocytes (MNPs) in the vicinity of HRSCs express similar regulatory mechanisms in parallel, and their presence in tissue is associated with inferior patient outcomes. MNPs in cHL have hitherto been identified by a small number of canonical markers and are usually described as tumor-associated macrophages. The organization of MNP networks and interactions with HRSCs remains unexplored at high resolution. Here, we defined the global immune-cell composition of cHL and nonlymphoma lymph nodes, integrating data across single-cell RNA sequencing, spatial transcriptomics, and multiplexed immunofluorescence. We observed that MNPs comprise multiple subsets of monocytes, macrophages, and dendritic cells (DCs). Classical monocytes, macrophages and conventional DC2s were enriched in the vicinity of HRSCs, but plasmacytoid DCs and activated DCs were excluded. Unexpectedly, cDCs and monocytes expressed immunoregulatory checkpoints PD-L1, TIM-3, and the tryptophan-catabolizing protein IDO, at the same level as macrophages. Expression of these molecules increased with age. We also found that classical monocytes are important signaling hubs, potentially controlling the retention of cDC2 and ThExh via CCR1-, CCR4-, CCR5-, and CXCR3-dependent signaling. Enrichment of the cDC2-monocyte-macrophage network in diagnostic biopsies is associated with early treatment failure. These results reveal unanticipated complexity and spatial polarization within the MNP compartment, further demonstrating their potential roles in immune evasion by cHL.

Identifiants

pubmed: 36758207
pii: 494363
doi: 10.1182/blood.2022015575
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2343-2358

Subventions

Organisme : Medical Research Council
ID : MR/N005872/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 216366/Z/19/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 by The American Society of Hematology.

Auteurs

Benjamin J Stewart (BJ)

Molecular Immunity Unit, Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Cambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom.

Martin Fergie (M)

Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, United Kingdom.

Matthew D Young (MD)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.

Claire Jones (C)

Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, United Kingdom.

Ashwin Sachdeva (A)

Genito-urinary Cancer Research Group, Division of Cancer Sciences, Oglesby Cancer Research Building, University of Manchester, Manchester, United Kingdom.
Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Alex Blain (A)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
School of Health and Life Sciences, Teesside University, Middlesbrough, United Kingdom.
National Horizons Centre, Teesside University, Darlington, United Kingdom.

Chris M Bacon (CM)

Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, United Kingdom.
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Vikki Rand (V)

School of Health and Life Sciences, Teesside University, Middlesbrough, United Kingdom.
National Horizons Centre, Teesside University, Darlington, United Kingdom.

John R Ferdinand (JR)

Molecular Immunity Unit, Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Kylie R James (KR)

Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.

Krishnaa T Mahbubani (KT)

Department of Surgery, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Cambridge Biorepository for Translational Medicine, Cambridge, United Kingdom.

Liz Hook (L)

Cambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
Department of Pathology, University of Cambridge, Cambridge, United Kingdom.

Nicolaas Jonas (N)

Cambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom.

Nicholas Coleman (N)

Cambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
Department of Pathology, University of Cambridge, Cambridge, United Kingdom.

Kourosh Saeb-Parsy (K)

Department of Surgery, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Cambridge Biorepository for Translational Medicine, Cambridge, United Kingdom.

Matthew Collin (M)

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Menna R Clatworthy (MR)

Molecular Immunity Unit, Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Cambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom.

Sam Behjati (S)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Cambridge University Hospitals NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom.

Christopher D Carey (CD)

Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, United Kingdom.
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH